Cookie Policy

What are cookies?

This Cookie Policy explains what cookies are and how we use them, the types of cookies we use i.e, the information we collect using cookies and how that information is used, and how to manage the cookie settings.

Cookies are small text files that are used to store small pieces of information. They are stored on your device when the website is loaded on your browser. These cookies help us make the website function properly, make it more secure, provide better user experience, and understand how the website performs and to analyze what works and where it needs improvement.

How do we use cookies?

As most of the online services, our website uses first-party and third-party cookies for several purposes. First-party cookies are mostly necessary for the website to function the right way, and they do not collect any of your personally identifiable data.

The third-party cookies used on our website are mainly for understanding how the website performs, how you interact with our website, keeping our services secure, providing advertisements that are relevant to you, and all in all providing you with a better and improved user experience and help speed up your future interactions with our website.

Types of Cookies we use
  • Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.Functional
  • Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.Analytics
  • Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.Performance
  • Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.Advertisement
  • Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Manage cookie preferences

Cookie Settings

You can change your cookie preferences any time by clicking the above button. This will let you revisit the cookie consent banner and change your preferences or withdraw your consent right away.

In addition to this, different browsers provide different methods to block and delete cookies used by websites. You can change the settings of your browser to block/delete the cookies. Listed below are the links to the support documents on how to manage and delete cookies from the major web browsers.

Chrome: https://support.google.com/accounts/answer/32050

Safari: https://support.apple.com/en-in/guide/safari/sfri11471/mac

Firefox: https://support.mozilla.org/en-US/kb/clear-cookies-and-site-data-firefox?redirectslug=delete-cookies-remove-info-websites-stored&redirectlocale=en-US

Internet Explorer: https://support.microsoft.com/en-us/topic/how-to-delete-cookie-files-in-internet-explorer-bca9446f-d873-78de-77ba-d42645fa52fc

If you are using any other web browser, please visit your browser’s official support documents.

27. David Sallman
David Sallman

Moffitt Cancer Center, Tampa, Florida, USA

David Sallman, MD, is an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, FL. His clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms. His research interests focus on the development of novel targeted therapeutic strategies for patients with MDS and AML, based on the underlying mutational drivers of each disease. He has authored numerous articles, books, book chapters, and abstracts and serves as reviewer for multiple journals. In 2017, he received the Young Investigator Grant from the MDS Foundation. 

19. Bart Scott
Bart Scott

University of Washington Medical Center, Seattle, Washington, USA

Bart Scott is a medical oncologist at Fred Hutchinson Cancer Research Center in Seattle, Washington. He is Professor of Medicine in the Division of Oncology at the University of Washington Medical Center and Director of Myeloid Malignancies at the Seattle Cancer Center Alliance. He is board certified in internal medicine and medical oncology by the American Board of Internal Medicine. Dr. Scott received his medical degree from the University of Alabama. He then completed his internship and residency at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He completed his fellowship in medical oncology at the University of Washington in Seattle. Dr. Scott has participated in a number of studies involving myelodysplastic syndromes and myeloproliferative disorders. He has published numerous articles in journals such as American Journal of Medicine ,  Leukemia & Lymphoma ,  Blood , and  Journal of Clinical Oncology . He is also a reviewer for  New England Journal of Medicine ,  British Journal of Haematology ,  Journal of the National Comprehensive Cancer Network , and  Haematologica , among others. Dr. Scott has been an invited lecturer on the management and treatment of myelodysplastic syndromes and transplantation for bone marrow failure. He is a member of the American Medical Association, the American Society of Hematology, the American Society of Clinical Oncology, and the Southwest Oncology Group, among many others.

Pierre_Fenaux
Pierre Fenaux

Hôpital Saint Louis, Paris, France

Pierre Fenaux, is professor of hematology and head of the hematology department at hospitals St Louis, Robert Debré and Avicenne  (belonging to Assistance Publique- Hôpitaux de Paris Hospital network). He is also part of  Inserm research  unit n° 944, at Hôpital St Louis, Paris, for his laboratory research activity  

He is involved in clinical and laboratory research in the field of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML, mainly AML in the elderly and acute promyelocytic leukemia, APL ). 

He is a founding member and chairman of the French speaking MDS group (Groupe Francophone des Myélodysplasies or GFM) and of the French APL group (GT-LAP).

Immunosuppressive therapy in MDS

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Yazan Migdady

Oregon Health & Science University, Portland, Oregon, USA

Managing isolated neutropenia and thrombocytopenia in Lower risk MDS

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Valeria Santini

University of Florence, Italy

Novel agents for higher risk MDS: be on the look?

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

David Sallman

Moffitt Cancer Center, Tampa, Florida, USA

Allogeneic stem cell transplant: how can we cure more patients?

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Bart Scott

University of Washington Medical Center, Seattle, Washington, USA

Luspatercept: where to fit the new kid on the block?

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Pierre Fenaux

Hospital Saint Louis, Paris, France